Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 5/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10300132 | 0.83 | TSHR (0.38) | TSHRTP53CA12CA1CA2 | |
| SCHEMBL4300377 | 0.81 | LMNA (0.36) | TSHRKIF11MAPTLMNAMAPK1 | |
| SCHEMBL10300169 | 0.79 | TSHR (0.33) | TSHRTP53CA12CA1CA2 | |
| SCHEMBL10300152 | 0.77 | TP53 (0.34) | TSHRTP53CA12CA1CA2 | |
| SCHEMBL10300153 | 0.77 | NPC1 (0.38) | TSHRTP53CA12CA1CA2 | |
| SCHEMBL4298138 | 0.75 | TSHR (0.41) | TSHRKIF11MAPTLMNAMAPK1 | |
| SCHEMBL13577108 | 0.73 | KIF11 (0.40) | KIF11KMT2AKDM4EMEN1ALDH1A1 | |
| SCHEMBL20457552 | 0.73 | ALDH1A1 (0.40) | TSHRMAPTMAPK1KCNN4TAAR1 | |
| SCHEMBL13299807 | 0.72 | MAPK1 (0.42) | TSHRMAPTMAPK1KCNN4TAAR1 | |
| SCHEMBL11055189 | 0.72 | KDM4E (0.52) | TSHRTP53KIF11CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2143724-B1 | NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL (JP) | 2013-12-11 | — | — | EP | disclosed |
| US-8217069-B2 | Nitrogenated fused ring derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-10 | — | — | US | disclosed |
| US-8217069-B2 | Nitrogenated fused ring derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-10 | — | — | US | disclosed |
| US-8217069-B2 | Nitrogenated fused ring derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20100112090-A1 | NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100112090-A1 | NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100112090-A1 | NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2143724-A1 | NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES | Kissei Pharmaceutical Co., Ltd. (JP) | 2010-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100112090-A1 | NITROGENATED FUSED RING DERIVATIVE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE OF THE SAME FOR MEDICAL PURPOSES | NR5A1, SHBG, GNRHR | TSHR 565/4885TP53 2514/4885KIF11 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.